Davis Polk advised Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC as joint book-running managers in connection with the $151.2 million public offering of common stock by Portola Pharmaceuticals, Inc. and certain of its selling stockholders. The common stock is listed on the NASDAQ Global Market under the symbol “PTLA.”
Based in South San Francisco, California, Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Peter M. Lamb and Jeffrey T. Hedrick. The tax team included partner Rachel D. Kleinberg and associate Catherine Paskoff Chang. The intellectual property team included partner Frank J. Azzopardi and law clerk Natalie A. Thomas. Counsel Marcie A. Goldstein and Catherine L. Martin provided FINRA and 1940 Act advice, respectively. Cassandra Aguirre and Kimberly Kakade were the legal assistants on the transaction. Members of the Davis Polk team based in the Menlo Park and New York offices.
Related Posts:
- Davis Polk – Portola Pharmaceuticals Initial Public Offering
- Davis Polk – Splunk Follow-on Stock Offering
- Davis Polk – NanoString Technologies, Inc. Initial Public Offering
- Davis Polk Advises E*TRADE on Common Stock Offering
- Davis Polk – Corcept Therapeutics Common Stock Offering
